Krystal Biotech, Inc. (KRYS) Discusses Positive Interim Results and Next Steps for Cystic Fibrosis Program KB407 Transcript

Core Viewpoint - Krystal Biotech announced positive interim clinical results for its cystic fibrosis program, KB407, highlighting the molecular confirmation of wild-type CFTR protein expression in patients' lungs [2]. Group 1: Clinical Update - The conference call was held to discuss the clinical update for the cystic fibrosis program, KB407 [2]. - The positive interim results were shared in a press release available on the company's website and filed as an 8-K with the SEC [2]. Group 2: Leadership and Participation - The call featured key executives including Krish Krishnan (Chairman and CEO), Suma Krishnan (President of Research and Development), Trevor Parry (Vice President of Product Development), David Sweet (Director of Clinical Development), and Dr. Jorge Lascano (Professor of Medicine and Director of the Cystic Fibrosis Therapeutics Development Center at the University of Florida) [2].